Key points
- Chikungunya virus disease should be suspected in patients with acute fever and polyarthralgia and recent travel to an area with chikungunya virus.
- Several other viruses, including dengue, should be considered in the differential diagnosis depending on travel history and exposures.
- Rare and serious complications of chikungunya virus disease can occur, particularly among certain risk groups.
- Disease is usually self-limited, but some patients experience persistent arthralgia for months to years.
Clinical presentation
Chikungunya virus disease should be considered in patients with acute onset of fever and polyarthralgia, especially travelers who recently returned from areas with known virus transmission.
The differential diagnosis varies based on place of residence, travel history, and exposures. Dengue, Zika, and chikungunya viruses are transmitted by the same mosquitoes and have similar clinical features. These viruses can circulate in the same area and can cause occasional co-infections in the same patient. Chikungunya virus infection is more likely to cause high fever, severe arthralgia, arthritis, rash, and lymphopenia, while dengue virus infection is more likely to cause neutropenia, thrombocytopenia, hemorrhage, shock, and death. In general, the signs and symptoms of Zika virus are mild, though infections can cause congenital infections. It is important to rule out dengue virus infection because proper clinical management of dengue can improve outcome.
In addition to dengue and Zika, other diagnostic considerations include leptospirosis, malaria, rickettsia, group A streptococcus, rubella, measles, parvovirus, enteroviruses, adenovirus, other alphavirus infections (Mayaro, Ross River, Barmah Forest, o’nyong-nyong, and Sindbis viruses), post-infectious arthritis, and rheumatologic conditions.
Signs and symptoms
The majority of people infected with chikungunya virus become symptomatic. The incubation period is typically 3–7 days (range, 1–12 days).
The disease is most often characterized by acute onset of fever (typically >39°C [102°F]) and polyarthralgia. Joint symptoms are usually bilateral and symmetric and can be severe and debilitating. Other symptoms can include headache, myalgia, arthritis, conjunctivitis, nausea/vomiting, or maculopapular rash. Rare complications include uveitis, retinitis, myocarditis, hepatitis, nephritis, bullous skin lesions, hemorrhage, meningoencephalitis, myelitis, Guillain-Barré syndrome, and cranial nerve palsies.
Persons at risk for severe disease include neonates exposed intrapartum or shortly after birth, older adults (>65 years), and persons with underlying medical conditions (e.g., hypertension, diabetes, or cardiovascular disease).
Clinical assessment
Clinical laboratory findings can include lymphopenia, thrombocytopenia, and elevated creatinine. Elevated hepatic transaminases can be seen with acute infection but are not specific and do not occur frequently enough to be diagnostic.
Outcomes
Acute symptoms typically resolve within 7–10 days. Some patients may have persistence or relapse of rheumatologic symptoms (polyarthralgia, polyarthritis, tenosynovitis) in the months following acute illness. Studies report variable proportions of patients with persistent joint pains for months to years. Mortality is rare and occurs mostly in older adults.
- Sharp TM, Keating MK, Shieh WJ, Bhatnagar J, Bollweg BC, Levine R, et al. Clinical characteristics, histopathology, and tissue immunolocalization of chikungunya virus antigen in fatal cases. Clin Infect Dis. 2021;73(2):e345-e354. doi: 10.1093/cid/ciaa837
- Hsu CH, Cruz-Lopez F, Vargas Torres D, Perez-Padilla J, Lorenzi OD, Rivera A, et al. Risk factors for hospitalization of patients with chikungunya virus infection at sentinel hospitals in Puerto Rico. PLoS Negl Trop Dis. 2019;13(1):e0007084. doi: 10.1371/journal.pntd.0007084
- Lindsey NP, Staples JE, Fischer M. Chikungunya virus disease among travelers–United States, 2014-2016. Am J Trop Med Hyg. 2018;98(1):192-197. doi: 10.4269/ajtmh.17-0668
- Adams LE, Martin SW, Lindsey NP, Lehman JA, Rivera A, Kolsin J, et al. Epidemiology of dengue, chikungunya, and Zika virus disease in U.S. states and territories, 2017. Am J Trop Med Hyg. 2019;101(4):884-890. doi: 10.4269/ajtmh.19-0309
- Centers for Disease Control and Prevention. Notes from the Field: Chikungunya Virus Spreads in the Americas — Caribbean and South America, 2013–2014. MMWR Morb Mortal Wkly Rep. 2014;63(22);500-501.
- Leparc-Goffart I, Nougairede A, Cassadou S, Prat C, de Lamballerie X. Chikungunya in the Americas. Lancet. 2014;383(9916):514. doi: 10.1016/S0140-6736(14)60185-9
- Thiberville SD, Moyen N, Dupuis-Maguiraga L, Nougairede A, Gould EA, Roques P, de Lamballerie X. Chikungunya fever: epidemiology, clinical syndrome, pathogenesis and therapy. Antiviral Res. 2013;99:345–370. doi: 10.1016/j.antiviral.2013.06.009
- Gibney KB, Fischer M, Prince HE, Kramer LD, St. George K, Kosoy OL, et al. Chikungunya fever in the United States: a fifteen year review of cases. Clin Infect Dis. 2011;52(5):e121-e126. doi: 10.1093/cid/ciq214
- Rajapakse S, Rodrigo C, Rajapakse A. Atypical manifestations of chikungunya infection. Trans R Soc Trop Med Hyg. 2010;104(2):89–96. doi: 10.1016/j.trstmh.2009.07.031
- Staples JE, Breiman RF, Powers AM. Chikungunya fever: an epidemiological review of a re-emerging infectious disease. Clin Infect Dis. 2009;49(6):942-948. doi: 10.1086/605496
- Lanciotti RS, Kosoy OL, Laven JJ, Panella AJ, Velez JO, Lambert AJ, Campbell GL. Chikungunya virus in US travelers returning from India, 2006. Emerg Infect Dis. 2007;13(5):764–767. doi: 10.3201/eid1305.070015